Fresenius (FSNUY) entered an exclusive development agreement with WuXi Biologics covering option rights for up to 37 biosimilar candidates. The agreement offers a pathway to expand its marketed and pipeline portfolio from 29 to up to 66 molecules over the next decade. Fresenius will select programs against its investment criteria and retain exclusive global commercialization rights and full economics of commercialized products.
Fresenius will pay development fees for selected candidates, with investment increasing as programs advance and affecting development-phase profitability. Funding comes from operating cash flow, with no new financing required. Full-year 2026 guidance remains unchanged, as does the 2030 Biopharma ambition to approximately double revenue versus 2025 at an EBIT margin around 20%. Fresenius expects to raise its longer-term Biopharma ambitions as the agreement expands opportunities beyond 2030.
Fresenius Kabi (FSNUY) announced the induction of 14 honorees into its National Blood Donation Hall of Fame, recognizing blood donation and advocacy. Nominated by blood centers across the United States, the 2026 inductees join more than 350 prior honorees recognized over 28 years. Their stories are featured in an annual calendar used by blood centers.
Fresenius (FSNUY) subsidiary Fresenius Kabi received Vizient’s 2026 Pharmacy Strategic Programs Excellence Award, announced at a September 22, 2026 ceremony.
The ceremony took place at the Vizient Connections Summit in Las Vegas. The award recognizes service, support, reliability, ethics and integrity, including Fresenius Kabi’s support for Vizient providers’ pharmacy performance and healthcare supply chains.
Fresenius (FSNUY) subsidiary Fresenius Kabi agreed with Waltz Health to provide direct access to three biosimilars through Waltz Connect.
The agreement covers adalimumab-aacf, Otulfi and Tyenne, which are used in treating certain inflammatory and autoimmune conditions. It expands Waltz Health’s Direct-to-Payer program into additional specialty therapeutic areas. The program uses pre-negotiated prices and a defined price per unit rather than traditional rebates. Employers and other plan sponsors contract with Waltz Health to offer eligible medicines to covered members. Final member costs vary with pharmacy fees and each plan sponsor’s benefit design.
mAbxience, majority-owned by Fresenius (FSNUY), and Sandoz (SDZNY) signed a global licensing, development, manufacturing and commercialization agreement for a proposed emicizumab biosimilar for hemophilia A.
mAbxience will develop and manufacture the biosimilar at its GMP-approved facilities in Spain and Argentina, while Sandoz receives exclusive commercialization rights worldwide except in Argentina, Uruguay and Paraguay. The candidate references Hemlibra and targets an estimated global reference market of about USD 5.7 billion. The deal expands mAbxience’s biosimilar pipeline into rare diseases and leverages Sandoz’s global commercial reach to broaden access to biologic medicines. Financial terms remain confidential.
Fresenius Kabi (FSNUY) and AABB announced the 21st annual Blood Collectors Week, to be held September 6–12, 2026, across the United States. The recognition week honors blood collection professionals such as phlebotomists, apheresis operators, recruiters, technicians, drivers, and medical directors. Nearly 200 blood collection facilities are expected to participate through recognition events, social media engagement, and employee appreciation activities. Resources, participating centers and engagement tools are available at bloodcollectors.org and via the @bloodcollectors account on X.
Fresenius Kabi (FSNUY) announced the U.S. launch of FDA‑approved generic Sugammadex Injection in a Simplist® ready‑to‑administer prefilled syringe on September 3, 2026. The product is initially offered as a 200 mg per 2 mL single‑dose syringe for operating room use.
Sugammadex Injection is indicated to reverse neuromuscular blockade induced by rocuronium bromide and vecuronium bromide in adult and pediatric patients aged 2 years and older undergoing surgery. The Simplist® format requires no assembly at the point of care, supporting streamlined medication management and reducing steps where errors can occur.
The company states that Sugammadex products are formulated, filled, and packaged in the United States to enhance domestic manufacturing and supply‑chain resiliency. Products are available for ordering immediately, with detailed prescribing and safety information provided in the official labeling.
Fresenius (OTC: FSNUY) has launched Fresenius Ventures, a corporate venture capital fund designed to invest in healthcare founders, technologies, and business models from early to growth stages. The unit combines capital with medical, regulatory, and operational expertise and offers access to clinical, scientific, and academic networks.
According to Fresenius, the fund plans to invest more than €200 million over the next five years, focusing on fields adjacent to its (Bio)Pharma, MedTech, and Care Provision platforms, including precision nutrition, microbiome research, new modalities, and digital care solutions. The fund is led by Dr. Thomas Michael Thestrup, formerly of Angelini Ventures, who brings over 15 years of healthcare and venture experience. Fresenius reported €22.6 billion in revenue in 2025 and operates in more than 60 countries.